Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | CDC25B | P30305 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1187679 | 0.83 | IDO1 (0.57) | PTPN2PTPN1CDC25BIDO1DHODH | |
| SCHEMBL7554702 | 0.80 | ALOX15 (0.58) | PTPN2PTPN1CDC25BIDO1ALOX15 | |
| SCHEMBL14747552 | 0.75 | IDO1 (0.63) | PTPN2PTPN1CDC25BIDO1ALOX15 | |
| SCHEMBL1187370 | 0.74 | PTPN2 (0.68) | PTPN2PTPN1CDC25BIDO1ALOX15 | |
| SCHEMBL1187681 | 0.73 | ALOX15 (0.49) | PTPN2PTPN1CDC25BALOX15DHODH | |
| SCHEMBL14878750 | 0.73 | IDO1 (0.47) | PTPN2PTPN1CDC25BIDO1DHODH | |
| SCHEMBL23425627 | 0.72 | PTPN1 (0.81) | PTPN2PTPN1CDC25BIDO1ALOX15 | |
| SCHEMBL3056286 | 0.72 | PTPN1 (0.81) | PTPN2PTPN1CDC25BIDO1ALOX15 | |
| SCHEMBL1187451 | 0.72 | PTPN1 (0.81) | PTPN2PTPN1CDC25BIDO1ALOX15 | |
| SCHEMBL23425674 | 0.72 | PTPN1 (0.81) | PTPN2PTPN1CDC25BIDO1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210322337-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | PTC THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-2332534-B1 | Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers | BIOELECTRON TECH CORP (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20180303767-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-10-25 | — | — | US | disclosed |
| US-10039722-B2 | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180200248-A1 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS | BIOELECTRON TECHNOLOGY CORPORATION | 2018-07-19 | — | — | US | disclosed |
| US-9932286-B2 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932286-B2 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932286-B2 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| EP-2617418-B1 | PHENOL AND 1,4-BENZOQUINONE DERIVATIVES FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECH CORP (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2617418-B1 | PHENOL AND 1,4-BENZOQUINONE DERIVATIVES FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECH CORP (US) | 2017-11-22 | — | — | EP | disclosed |
| US-20110046156-A1 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS | EDISON PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| EP-2262519-A2 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS | Edison Pharmaceuticals, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010045220-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | EDISON PHARMACEUTICALS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009111543-A2 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS | EDISON PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-1986636-A2 | SIDE CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | Edison Pharmaceuticals, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20070225261-A1 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225261-A1 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225261-A1 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2007-09-27 | — | — | US | disclosed |
| WO-2007100652-A2 | SIDE CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | EDISON PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007100652-A2 | SIDE CHAIN VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | EDISON PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046156-A1 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS | TXN2, TXNRD2, OTC | PTPN2 4220/4885PTPN1 4065/4885CDC25B 2512/4885 |
| US-20180303767-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | GPX4, TXN2, TXNRD1 | PTPN2 2705/4885PTPN1 2725/4885CDC25B 4075/4885 |
| US-10039722-B2 | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells | GPX4, TXN2, TXNRD1 | PTPN2 2705/4885PTPN1 2725/4885CDC25B 4075/4885 |
| US-20180200248-A1 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS | TXN2, TXNRD2, OTC | PTPN2 4220/4885PTPN1 4065/4885CDC25B 2512/4885 |
| US-20210322337-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | GPX4, TXN2, TXNRD1 | PTPN2 2705/4885PTPN1 2725/4885CDC25B 4075/4885 |
| US-20070225261-A1 | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | FH, NDUFAB1, ACAA2 | PTPN2 4781/4885PTPN1 4730/4885CDC25B 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.